ReviewTranslational lung cancer research2026
Understanding the dual role of granulocyte-macrophage colony-stimulating factor in the lung cancer tumor microenvironment and its therapeutic implications.
Review in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a pleiotropic cytokine that plays a complex and critical dual regulatory role in the development, progression, and immunotherapy of lung cancer. In recent years, with the deepening of research into the tumor microenvironment (TME), GM-CSF has been recognized to possess dual regulatory functions. On the one hand, GM-CSF can enhance anti-tumor immune responses by activating and recruiting immune cells. On the other hand, it may indirectly support tumor growth and immune evasion by promoting the accumulation of myeloid-derived suppressor cells (MDSCs) and tumor-associated inflammation. Consequently, the precise mechanisms and regulatory networks of GM-CSF within the lung cancer TME remain controversial, and its efficacy in different immunotherapeutic strategies requires further exploration. This review systematically summarizes the biological characteristics of GM-CSF and its expression features in lung cancer, focusing on its dual regulatory effects on immune cells within the TME, including differential modulation of tumor-associated macrophages (TAMs), MDSCs, tumor-associated neutrophils (TANs), and dendritic cells (DCs). Furthermore, this review discusses the potential application value of GM-CSF in lung cancer treatment, such as its combination with chemoradiotherapy, targeted therapy, and immune checkpoint inhibitors (ICIs) based on clinical trial evidence. Finally, we propose key directions for future research, including dissecting GM-CSF's functional determinants using single-cell multi-omics, developing biomarkers for patient stratification, and exploring novel targeted delivery systems. This review aims to provide new insights and directions for future clinical translational research and precision therapy applications of GM-CSF in lung cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.